ProCE Banner Activity

Targeting RET in Advanced Thyroid Cancers

Clinical Thought
My take on how selective RET inhibitors are changing the standard of care in advanced thyroid cancer.

Released: November 04, 2020

Expiration: November 03, 2021

Share

Faculty

Lori J. Wirth

Lori J. Wirth, MD

Associate Professor
Medical Oncology
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Lori J. Wirth, MD

Associate Professor
Medical Oncology
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Lori J. Wirth, MD, has disclosed that she has received consulting fees from Ayala, Bayer, Blueprint, Cue, Cullinan, Eisai, Genentech, Lilly, Loxo, Merck, and Novartis and other financial or material support from Iovance.